Abstract
Rhizoxin is an antineoplastic drug that inhibits tubulin polymerization. In this study, we demonstrated that rhizoxin was approximately twice as active in vitro against a human small-cell lung cancer cell line with non-P-glycoprotein-mediated resistance to vindesine, H69/VDS, as against its parental line, H69. Tubulin polymerization in H69/VDS, demonstrated by Western blot analysis, was inhibited markedly by rhizoxin compared with that in H69, in a concentration-dependent manner. A drug-accumulation study showed that the intracellular rhizoxin level in H69/VDS was 15% lower than that in H69, whereas efflux from H69/VDS was enhanced slightly. These results indicate that enhanced inhibition of tubulin polymerization rather than increased intracellular drug concentration accounted for the higher sensitivity of H69/VDS to rhizoxin. In an experiment using mice with severe combined immunodeficiency and inoculated subcutaneously with H69/VDS, in vivo tumor growth was reduced markedly by three intermittent intraperitoneal doses of rhizoxin compared with that in mice inoculated with H69. Three weeks after the last rhizoxin dose, the relative treated/untreated tumor volumes were 0.29 for H69, but only 0.06 for H69/VDS, indicating that H69/VDS regrowth was minimal even after a 3-week treatment-free period. In conclusion, rhizoxin conquers vindesine resistance of a human small-cell lung cancer cell line in vitro and in vivo.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bai RL, Pettit GR, Hamel E (1990) Binding of dolastatin 10 to tubulin at a distinct site for peptide antimitotic agents near the exchangeable nucleotude and vinca alkaloid sites. J Biol Chem 265:17141–17149
Bissett D, Graham MA, Setanoians A, Chadwick GA, Wilson P, Koier I, Henrar R, Schwartsmann G, Cassidy J, Kaye SB, Kerr DJ (1992) Phase I and pharmacokinetic study of rhizoxin. Cancer Res 52:2894–2898
Cabral F, Barlow SB (1989) Mechanisms by which mammalian cells acquire resistance to drugs that affect microtubule assembly. FASEB J 3:1593–1599
Cabral F, Sobel ME, Gottesman MM (1980) CHO mutants resistant to colchicine, colcemid or griseofulvin have an altered β-tubulin. Cell 20:29–36
Cole SPC (1996) Multidrug resistance in human lung cancer and topoisomerase II. In: Pass HI, Mitchell JB, Johnson DH, Turrisi AT (eds) Lung cancer: principles and practice. Lippincott-Raven, Philadelphia, pp 169–204
Donehower RC, Rowinsky EK (1993) Anticancer drugs derived from plants. In: DeVita VT Jr, Hellman S, Rosenberg SA (eds) Cancer: principles and practice of oncology, vol 1. Lippincott, Philadelphia, pp 409–417
Heike Y, Takahashi M, Ohira T, Arioka H, Funayama Y, Nishio K, Ogasawara H, Saijo N (1995) In vivo screening models of cisplatin-resistant human lung cancer cell lines using SCID mice. Cancer Chemother Pharmacol 35:200–204
Hendriks HR, Plowman J, Berger DP, Paull KD, Fiebig HH, Fodstad Ø, Dreef-van der Meulen HC, Henrar PE, Pinedo HM, Schwartsmann G (1992) Preclinical antitumour activity and animal toxicology studies of rhizoxin, a novel tubulin-interacting agent. Ann Oncol 3:755–763
Houghton JA, Houghton PJ, Hazelton BJ, Douglass EC (1985) In situ selection of a human rhabdomyosarcoma resistant to vincristine with altered β-tubulins. Cancer Res 45:2706–2712
Iwasaki S, Kobayashi H, Furukawa J, Namikoshi M, Okuda S, Sato Z, Matsuda I, Noda T (1984) Studies on macrocyclic lactone antibiotics. VII. Structure of a phytotoxin “rhizoxin” produced by Rhizopus chinesis. J. Antibiot (Tokyo) 37:354–362
Minotti AM, Barlow SB, Cabral F (1991) Resistance to antimitotic drugs in Chinese hamster ovary cells correlates with changes in the level of polymerized tubulin. J Biol Chem 266:3987–3994
Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55–63
Ohta S, Nishio K, Kubo S, Nishio M, Ohmori T, Takahashi T, Saijo N (1993) Characterisation of a vindesine-resistant human small-cell lung cancer cell line. Br J Cancer 68:74–79
Ohta S, Nishio K, Kubota N, Ohmori T, Funayama Y, Ohira T, Nakajima H, Adachi M, Saijo N (1994) Characterization of a taxol-resistant human small-cell lung cancer cell line. Jpn J Cancer Res 85:290–297
Okabe-Kado J, Hayashi M, Honma Y, Hozumi M, Tsuruo T (1991) Inhibition by erthroid differentiation factor (activin A) of P-glycoprotein expression in multidrug-resistant human K562 erythroleukemia cells. Cancer Res 51:2582–2586
Sieber SM, Wolpert MK, Adamson RH, Cysyk RL, Bono VH, Johns DG (1976) Experimental studies with maytansine — a new antitumor agent. Biol Haematol 43:495–500
Stearns ME, Tew KD (1988) Estramustine binds MAP-2 to inhibit microtubule assembly in vitro. J Cell Sci 89:331–342
Sullivan AS, Prasad V, Roach MC, Takahashi M, Iwasaki S, Luduena RF (1990) Interaction of rhizoxin with bovine brain tubulin. Cancer Res 50:4277–4280
Takahashi M, Iwasaki S, Kobayashi H, Okuda S, Murai T, Sato Y, (1987a) Rhizoxin binding to tubulin at the maytansine-binding site. Biochem Biophys Acta 926:215–223
Takahashi M, Iwasaki S, Kobayashi H, Okuda S, Murai T, Sato Y, Haraguchi-Hiraoka T, Nagano H (1987b) Studies on macrocyclic lactone antibiotics. XI. Anti-mitotic and anti-tubulin activity of new antitumor antibiotics, rhizoxin and its homologues. J Antibiot (Tokyo) 40:66–72
Thrower D, Jordan MA, Wilson L (1991) Quantitation of cellular tubulin in microtubules and tubulin pools by a competitive ELISA. J Immunol Methods 136:45–51
Tsuruo T, Iida H, Ohkochi E, Tsukagoshi S, Sakurai Y (1983) Establishment and properties or vincristine-resistant human myelogenous leukemia K562. Gann 74:751–758
Tsuruo T, Oh-hara T, Iida H, Tsukagoshi S, Sato Z, Matsuda I, Iwasaki S, Okuda S, Shimizu F, Sasagawa K, Fukami M, Fukuda K, Arakawa M (1986) Rhizoxin, a macrocyclic lactone antibiotic, as a new antitumor agent against human and murine tumor cells and their vincristine-resistant sublines. Cancer Res 46:381–385
Waud WR, Harrison SJ, Gilbert KS, Laster WJ, Griswold DJ (1991) Antitumor drug cross-resistance in vivo in a cisplatin-resistant murine P388 leukemia. Cancer Chemother Pharmacol 27:456–463
Author information
Authors and Affiliations
Additional information
This work was supported in part by Grants-in-Aid from the Ministry of Health and Welfare for the Second Term of Comprehensive 10-Year Strategy for Cancer Control, the Ministry of Education, Science, Sports and Culture, Japan, and the Foundation of the Bristol-Myers Squibb Company.
Rights and permissions
About this article
Cite this article
Arioka, H., Nishio, K., Heike, Y. et al. In vitro and in vivo modulation by rhizoxin of non-P-glycoprotein-mediated vindesine resistance. J Cancer Res Clin Oncol 123, 195–200 (1997). https://doi.org/10.1007/BF01240315
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01240315